Predicted Trait | |
Reported Trait | Cervical cancer |
Mapped Trait(s) | cervical carcinoma (EFO_0001061) |
Score Construction | |
PGS Name | CC_Cervix |
Development Method | |
Name | Genome-wide significant variants |
Parameters | P < 5e-8, MAF > 1%, biallelic SNPs, LD-thin r2 > 0.3 |
Variants | |
Original Genome Build | GRCh37 |
Number of Variants | 10 |
Effect Weight Type | log(OR) |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000050 |
Citation (link to publication) | Graff RE et al. Nat Commun (2021) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 100% 20,405 individuals (100%) |
PGS Evaluation | European: 100% 2 Sample Sets |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST003565 Europe PMC: 27285765 |
6,076 individuals | European | NR |
GWAS Catalog: GCST001900 Europe PMC: 23482656 |
4,982 individuals | European | TwinGene |
GWAS Catalog: GCST004833 Europe PMC: 28806749 |
9,347 individuals | European | NR |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM000193 | PSS000112| European Ancestry| 226,216 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Cervical cancer | OR: 1.22 [1.19, 1.25] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. | Results from meta-analysis of GERA and UKB |
PPM002039 | PSS001012| European Ancestry| 211,795 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident cervical cancer | HR: 1.22 [1.09, 1.37] | AUROC: 0.745 C-index: 0.75 (0.017) |
— | Age at assessment, genotyping array, PCs(1-15), parity ( ≥1 live birth vs. none), oral contraceptive use (never used (0) vs. <20 years vs. ≥20 years), cigarette pack-years | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000112 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 27010 | — | [ ,
0.0 % Male samples |
— | European | — | GERA, UKB | — |
PSS001012 | Individuals with at least one recorded incident diagnosis of a borderline, in situ, or malignant primary cancer were defined as cases. | — | [ ,
0.0 % Male samples |
— | European | — | UKB | — |